considering acl, page-5

Hey Jessie, I'll compile what I think relative to ACL tonight for you, from just my opinions of course, just need some time. There are heaps of guys here who have great insights and differing price models/projections so maybe a lot of reading over the threads is best.

To answer specifically to your points in your last post:

Management: Are doing what they can, simply they are hamstrung until FDA come through with the Generic's approval, ACL are ramping up for the phase 3 trial of HA-Irinotecan, not to mention the phase 2 to get going also. Oral Fonda is another exciting opportunity, management simply need the approval for certainty of cash flows. They haven't sat on their hands and the recent survey/study done for HA-I is very interesting as to the future potential and take up by the industry.

Cash Burn: Was averaging $5m per year but now looks to be around $8.5m because they are getting sorted with the phase 3 trials, they mention the extra cash burn is reflected in the last quarterly and is due to HA-I trial preps.

Low Volume: It's been a while in the making, who really knows why it's not running for the hills, but if you look the uptrend is in tact and is now consolidating the latest rise, maybe ready for the final charge??

Don't know how much you know so is hard to know what level to talk on....:)